Gaois

A collection of legal and legislative terms in Irish extracted from the European Union’s multilingual terminology database. More information »

SOCIAL QUESTIONS|health|pharmaceutical industry
brisphointe cliniciúil Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
ga
tiúchan antaibheathach an bhrisphointe Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
ga
Grenzkonzentration | Break-Point
de
breakpoint | breakpoints | breakpoint antibiotic concentration | concentrations | clinical breakpoint
en
Definition discriminating concentration used in the interpretation of results of susceptibility testing to define isolates as susceptible, intermediate or resistant Reference "British Society for Antimicrobial Chemotherapy (BSAC) website > Alasdair P. MacGowana and Richard Wise. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests, http://bsac.org.uk/wp-content/uploads/2012/02/Chapter-3-Establishing-MIC-bps-2005updated.pdf [9.3.2010]"
Comment "These concentrations range from x mg/L (low) to y mg/L (high) and an isolate is characterised as:- susceptible (S), if at a concentration < less than x mg/L there is a high likelihood of therapeutic success- intermediate (I), if at a concentration more than x and less than y mg/L the therapeutic effect is uncertain, and- resistant (R), if at a concentration more than y mg/L there a high likelihood of therapeutic failure.For more information, see also: EUCAST definitions of clinical breakpoints and epidemiological cut-off values, http://www.srga.org/Eucastwt/eucastdefinitions.htm [22.11.2013]"
valeur seuil | concentration critique
fr
Definition valeur numérique utilisée pour restituer qualitativement les résultats d'un antibiogramme en deux ou trois catégories cliniques: sensible, intermédiaire, résistant Reference "COM-FR, d'après:Définitions de la résistance aux antibiotiques en médecine vétérinaire: épidémiologique ou pronostique, P. Sanders et M. Laurentie, http://documents.irevues.inist.fr/bitstream/handle/2042/48416/AVF_2012_3_261.pdf?sequence=1 [18.3.2015]"